Literature DB >> 1906847

A new form of specific targeting cancer immunotherapy using anti-tumor monoclonal antibody-conjugated lymphokine-activated killer cells.

H Shiraiwa1, T Sekine, K Tobisu, T Kakizoe, K Koiso.   

Abstract

Cross-linking of effector T cells to target cancer cells augments their tumor lytic activities. Here we describe a new method of conjugating lymphokine-activated killer (LAK) cells with cancer-specific monoclonal antibody. The LAK cells were biotinylated, treated with avidin, and conjugated with biotinylated monoclonal antibody. These monoclonal antibody-conjugated LAK cells showed specifically enhanced killing activities against anti-tumor antibody-reactive cancer cells, and cold target cells specifically inhibited their activities.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1906847      PMCID： PMC5918496          DOI： 10.1111/j.1349-7006.1991.tb01895.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN： 0910-5050


lymphokine‐activated killer phosphate‐buffered saline N‐hydroxysuccinimide antibody‐dependent, cell‐mediated cytotoxicity monoclonal antibody‐conjugated, lyraphokine‐activated killer
  8 in total

1.  Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody.

Authors:  P Perez; J A Titus; M T Lotze; F Cuttitta; D L Longo; E S Groves; H Rabin; P J Durda; D M Segal
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

2.  Monoclonal antibody production by receptor-mediated electrically induced cell fusion.

Authors:  M M Lo; T Y Tsong; M K Conrad; S M Strittmatter; L D Hester; S H Snyder
Journal:  Nature       Date:  1984 Aug 30-Sep 5       Impact factor: 49.962

3.  Hybrid antibodies can target sites for attack by T cells.

Authors:  U D Staerz; O Kanagawa; M J Bevan
Journal:  Nature       Date:  1985 Apr 18-24       Impact factor: 49.962

4.  A monoclonal antibody reactive with gastric carcinoma.

Authors:  T Sekine; S Hirohashi; H Kitaoka; T Hirota; T Sugimura
Journal:  Gan       Date:  1984-02

5.  Bispecific F (ab')2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells.

Authors:  T Nitta; H Yagita; T Azuma; K Sato; K Okumura
Journal:  Eur J Immunol       Date:  1989-08       Impact factor: 5.532

6.  Comparison of seven cell lines derived from human gastric carcinomas.

Authors:  T Motoyama; H Hojo; H Watanabe
Journal:  Acta Pathol Jpn       Date:  1986-01

7.  Preliminary trial of specific targeting therapy against malignant glioma.

Authors:  T Nitta; K Sato; H Yagita; K Okumura; S Ishii
Journal:  Lancet       Date:  1990-02-17       Impact factor: 79.321

8.  Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies.

Authors:  P Perez; R W Hoffman; J A Titus; D M Segal
Journal:  J Exp Med       Date:  1986-01-01       Impact factor: 14.307
  8 in total
  1 in total

1.  JAK2 inhibitor combined with DC-activated AFP-specific T-cells enhances antitumor function in a Fas/FasL signal-independent pathway.

Authors:  Yang Liu; Yue-Ru Wang; Guang-Hui Ding; Ting-Song Yang; Le Yao; Jie Hua; Zhi-Gang He; Ming-Ping Qian
Journal:  Onco Targets Ther       Date:  2016-07-20       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.